2026-10-14 12:30:00 UTC#458973newconfirmednews
SRPT stock news
SRPT stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire20 wire items
2026-10-08 14:20:00 UTC#433067newconfirmednews
RBC Capital maintains Sarepta Therapeutics at Sector Perform, cuts price target to $17 from $19
2026-10-05 11:54:25 UTC#413123newconfirmednews
H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics with $5 price target
tradingviewimportance 0.40trust 0.60H.C. Wainwright & Co. -0.30Sarepta Therapeutics, Inc. -0.50ELEVIDYS -0.40
2026-09-30 18:18:00 UTC#393615newconfirmednews
JPMorgan maintains Neutral rating on Sarepta Therapeutics (SRPT)
2026-09-23 21:09:47 UTC#358643duplicateconfirmednews
REGENXBIO and Sarepta Therapeutics settle patent litigation with $39 million payment
reutersimportance 0.30trust 0.90REGENXBIO Inc. +0.50Sarepta Therapeutics, Inc. -0.40University of Pennsylvania 0+2 entities
2026-09-23 20:23:10 UTC#358365newconfirmednews
Sarepta Therapeutics to pay $39M to settle AAVrh74 patent disputes with REGENXBIO and UPenn
tradingviewimportance 0.60trust 0.80Sarepta Therapeutics, Inc. +0.40REGENXBIO Inc. -0.30University of Pennsylvania 0+2 entities
2026-09-14 13:53:47 UTC#307809duplicateconfirmednews
Sarepta Therapeutics (SRPT) reiterates H2 2026 data timeline for FSHD and DM1, notes ELEVIDYS stabilization
2026-09-14 13:24:49 UTC#307609newconfirmednews
Sarepta Therapeutics (SRPT) expects FSHD and DM1 clinical data in H2 2026; ELEVIDYS sales stabilizing
2026-09-10 15:03:44 UTC#293176duplicateconfirmednews
Sarepta Therapeutics to initiate DUET clinical study for dual VEGF/Wnt therapy in DME this year
2026-09-10 14:08:09 UTC#292788newconfirmednews
Sarepta to launch DUET study for dual VEGF/Wnt therapy in DME later this year, targeting Vabysmo differentiation
2026-09-09 15:22:54 UTC#286861newconfirmednews
Sarepta Therapeutics shares rise 10% in market rebound
2026-09-08 17:03:43 UTC#282484duplicateconfirmednews
Dyne and Sarepta shares decline following Novartis clinical trial setback
reutersimportance 0.30trust 0.90Dyne Therapeutics, Inc. -0.40Sarepta Therapeutics, Inc. -0.40Novartis AG -0.50
2026-09-08 17:00:31 UTC#282435duplicateconfirmednews
Dyne, Sarepta, and PepGen shares decline following Novartis clinical trial failure
reutersimportance 0.30trust 0.80Dyne Therapeutics, Inc. -0.50Sarepta Therapeutics, Inc. -0.40Novartis AG -0.60+2 entities
2026-09-08 08:56:12 UTC#279401duplicateconfirmednews
Novartis shares fall 13% on clinical trial failure, impacting Dyne and Sarepta
seeking alphaimportance 0.40trust 0.60Novartis AG -0.70Dyne Therapeutics, Inc. -0.40Sarepta Therapeutics, Inc. -0.40
2026-08-06 04:31:05 UTC#134492updateconfirmednews
Sarepta forecasts $1.2B-$1.3B 2026 revenue, delays Cohort 8 12-week data to Q1 2027
2026-08-05 23:23:15 UTC#133627newconfirmednews
Sarepta Therapeutics Q2 revenue declines on lower Elevidys demand; 2026 guidance narrowed
2026-07-27 23:15:05 UTC#84766duplicateconfirmednews
Sarepta Therapeutics appoints former AbbVie executive Michael Severino as CEO
bloombergimportance 0.30trust 0.90Sarepta Therapeutics, Inc. +0.30Michael Severino +0.30AbbVie Inc. 0+1 entities
2026-07-27 12:53:00 UTC#81974duplicateconfirmednews
Sarepta Therapeutics Names Former AbbVie Executive Michael Severino as CEO, Succeeding Doug Ingram
dow_jonesimportance 0.40trust 0.90Sarepta Therapeutics, Inc. +0.20Michael Severino +0.20Doug Ingram 0+2 entities
2026-07-27 12:40:41 UTC#81910duplicateconfirmednews
Sarepta Therapeutics appoints Michael Severino as CEO
2026-07-27 12:31:34 UTC#81895duplicateconfirmednews